Processa Pharmaceuticals, Inc. Common Stock
PCSA US74275C3043
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Yorke Justin W |
0.80 USD |
12,400 Bought |
9,889 USD |
27/01/2025 | 27/01/2025 |
| Lin Patrick SR OFF |
0.80 USD |
43,500 Bought |
34,691 USD |
27/01/2025 | 27/01/2025 |
| Young David PR |
0.80 USD |
124,500 Bought |
99,289 USD |
27/01/2025 | 27/01/2025 |
| Ng George K CEO |
0.80 USD |
87,200 Bought |
69,542 USD |
27/01/2025 | 27/01/2025 |
| Young David PR |
2.45 USD |
21,000 Bought |
51,526 USD |
07/02/2024 | 07/02/2024 |
| Young David PR |
2.53 USD |
20,000 Bought |
50,504 USD |
06/02/2024 | 06/02/2024 |
| Lin Patrick SR OFF |
2.40 USD |
1,500 Bought |
3,600 USD |
31/01/2024 | 01/02/2024 |
| Lin Patrick SR OFF |
2.37 USD |
2,500 Bought |
5,925 USD |
31/01/2024 | 31/01/2024 |
| Ng George K CEO |
2.70 USD |
10,000 Bought |
27,000 USD |
30/01/2024 | 30/01/2024 |
| Yorke Justin W |
2.69 USD |
8,000 Bought |
21,544 USD |
30/01/2024 | 30/01/2024 |